Claims
- 1. A disubstituted bicyclic heterocycle of the formula ##STR8## wherein X is a nitrogen atom or a methine group optionally substituted by a C.sub.1-3 -alkyl group;
- R.sub.1 is a hydrogen atom or a C.sub.1-6 -alkyl group;
- B is an ethylene group optionally substituted by one or two C.sub.1-3 -alkyl groups, wherein a methylene moiety of the ethylene group, which is linked to either the bicyclic heteroaromatic group or the Ar group, is optionally replaced by an oxygen or sulphur atom, or by a sulphinyl, sulphonyl, carbonyl, or --NR.sub.1 -- group, wherein R.sub.1 is as hereinbefore defined, or
- B is a straight-chained C.sub.3-5 -alkylene group, in which a methylene moiety, which is linked neither to the bicyclic heteroaromatic group nor to the Ar group, is replaced by an --NR.sub.1 -- group, wherein R.sub.1 is as hereinbefore defined;
- E is a cyano or R.sub.b NH--C(.dbd.NH)-- group, wherein
- R.sub.b is a hydrogen atom, a hydroxy group, a C.sub.1-3 -alkyl group, or a group which may be cleaved in vivo;
- Ar is a phenylene or naphthylene group optionally substituted by a fluorine, chlorine, or bromine atom, or by a trifluoromethyl, C.sub.1-3 -alkyl, or C.sub.1-3 -alkoxy group; or a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene, or pyridazinylene group optionally substituted in the carbon skeleton by a C.sub.1-3 -alkyl group; and
- R.sub.a is a phenyl-C.sub.1-3 -alkoxy group, an amino group, a C.sub.1-3 -alkylamino group substituted at the nitrogen atom by a phenyl-C.sub.1-3 -alkyl group, or an R.sub.3 --CO--R.sub.4 N-- or R.sub.3 --SO.sub.2 --R.sub.4 N-- group wherein
- R.sub.3 is a C.sub.1-5 -alkyl, phenyl-C.sub.1-3 -alkyl, C.sub.3-7 -cycloalkyl, phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, tetrahydroquinolyl or tetrahydroisoquinolyl group and
- R.sub.4 is a hydrogen atom, C.sub.1-5 -alkyl or phenyl-C.sub.1-3 -alkyl group, each of which is substituted in the alkyl moiety by a group which may be converted in vivo into a carboxy group, by a carboxy or tetrazolyl group, by an aminocarbonyl or C.sub.1-3 -alkylaminocarbonyl group, each of which is additionally substituted at the nitrogen atom by a group which may be converted in vivo into a carboxy-C.sub.1-3 -alkyl group or by a carboxy group, a C.sub.2-5 -alkyl group terminally substituted by a di-(C.sub.1-3 -alkyl)-amino group, or a C.sub.3-7 -cycloalkyl group,
- or a tautomer or pharmaceutically acceptable salt thereof.
- 2. A disubstituted bicyclic heterocycle of the formula I according to claim 1, wherein
- X is a nitrogen atom or a methine group optionally substituted by a methyl group;
- R.sub.1 is a hydrogen atom or a methyl group;
- B is an ethylene group optionally substituted by one or two methyl groups, wherein a methylene moiety of the ethylene group, which is linked to either the bicyclic heteroaromatic group or Ar group, may be replaced by an oxygen or sulphur atom, by a carbonyl or --NR.sub.1 -- group, wherein R.sub.1 is as hereinbefore defined, or
- B also is an n-propylene group wherein the central methylene moiety is replaced by an --NR.sub.1 -- group wherein R.sub.1 is as hereinbefore defined;
- E is a cyano or R.sub.b NH--C(.dbd.NH)-- group wherein
- R.sub.b is a hydrogen atom, a C.sub.1-8 -alkyloxy-carbonyl, C.sub.5-7 -cycloalkyloxy-carbonyl, benzoyl, nicotinoyl, or isonicotinoyl group;
- Ar is a phenylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, methyl or methoxy group, or a thienylene group optionally substituted in the carbon skeleton by a methyl group; and
- R.sub.a is a benzyloxy group, an amino group, a C.sub.1-3 -alkylamino group, which is additionally substituted at the nitrogen atom by a benzyl group, or an R.sub.3 --CO--R.sub.4 N-- or R.sub.3 --SO.sub.2 --R.sub.4 N-- group wherein
- R.sub.3 is a C.sub.1-4 -alkyl, benzyl, C.sub.5-7 -cycloalkyl, phenyl, pyridyl, quinolyl, isoquinolyl, tetrahydroquinolyl, or tetrahydroisoquinolyl group, and
- R.sub.4 is a hydrogen atom, a C.sub.1-3 -alkyl group substituted by a carboxy, C.sub.1-3 -alkoxy-carbonyl, tetrazolyl, aminocarbonyl or C.sub.1-3 -alkylaminocarbonyl group, whilst the aminocarbonyl and C.sub.1-3 -alkylaminocarbonyl group are each additionally substituted at the nitrogen atom by a carboxy-C.sub.1-3 -alkyl or C.sub.1-3 -alkoxy-carbonyl-C.sub.1-3 -alkyl group, or a C.sub.2-3 -alkyl group terminally substituted by a di-(C.sub.1-3 -alkyl)-amino group,
- or a tautomer or pharmaceutically acceptable salt thereof.
- 3. The disubstituted bicyclic heterocycle of the formula I according to claim 1, wherein
- X is a nitrogen atom or a methine group optionally substituted by a methyl group;
- R.sub.1 is a hydrogen atom or a methyl group;
- B is an ethylene group optionally substituted by one or two methyl groups, wherein a methylene moiety of the ethylene group, which is linked to either the bicyclic heteroaromatic group or the Ar group, may be replaced by an oxygen or sulphur atom, by a carbonyl or --NR.sub.1 -- group, wherein R.sub.1 is as hereinbefore defined, or
- B is an n-propylene group wherein the central methylene moiety is replaced by an --NR.sub.1 -- group, wherein R.sub.1 is as hereinbefore defined;
- E is an R.sub.b NH--C(.dbd.NH)-- group wherein
- R.sub.b is a hydrogen atom, a C.sub.1-8 -alkyloxy-carbonyl, C.sub.5-7 -cycloalkyloxy-carbonyl or benzoyl group;
- Ar is a phenylene group optionally substituted by a fluorine, chlorine, or bromine atom, by a trifluoromethyl, methyl, or methoxy group, or a thienylene group optionally substituted in the carbon skeleton by a methyl group; and
- R.sub.a is a benzyloxy group, an amino group, a C.sub.1-3 -alkylamino group additionally substituted at the nitrogen atom by a benzyl group, an R.sub.3 --CO--R.sub.4 N-- or R.sub.3 --SO.sub.2 --R.sub.4 N-- group wherein
- R.sub.3 is a C.sub.1-4 -alkyl, benzyl, C.sub.5-7 -cycloalkyl, phenyl, pyridyl, quinolyl, isoquinolyl, tetrahydroquinolyl or tetrahydroisoquinolyl group and
- R.sub.4 is a hydrogen atom, a C.sub.1-3 -alkyl group which is substituted by a carboxy, C.sub.1-3 -alkoxy-carbonyl, tetrazolyl, aminocarbonyl or C.sub.3 -alkylaminocarbonyl group, wherein the aminocarbonyl and C.sub.1-3 -alkylaminocarbonyl group are each additionally substituted at the nitrogen atom by a carboxy-C.sub.1-3 -alkyl or C.sub.1-3 -alkoxycarbonyl-C.sub.1-3 -alkyl group, or a C.sub.2-3 -alkyl group terminally substituted by a di-(C.sub.1-3 -alkyl)-amino group,
- or a tautomer or pharmaceutically acceptable salt thereof.
- 4. The disubstituted bicyclic heterocycle of the formula I according to claim 3, wherein R.sub.a in the 5 position is an R.sub.3 --CO--R.sub.4 N-- or R.sub.3 --SO.sub.2 --R.sub.4 N-- group, wherein R.sub.3 and R.sub.4 are as hereinbefore defined, or a tautomer or pharmaceutically acceptable salt thereof.
- 5. The disubstituted bicyclic heterocycle of the formula Ia ##STR9## wherein X is a methine group or a nitrogen atom;
- R.sub.1 is a methyl group;
- B is an ethylene group, wherein the methylene moiety linked to Ar is optionally replaced by an oxygen atom or a imino group,
- Ar is a 1,4-phenylene group;
- E is an R.sub.b NH--C(.dbd.NH)-- group; and
- R.sub.a is an R.sub.3 --CO--R.sub.4 N-- or R.sub.3 --SO.sub.2 --R.sub.4 N-- group, wherein
- R.sub.4 is a methyl group substituted by a carboxy, C.sub.1-3 -alkoxy-carbonyl, carboxymethylaminocarbonyl or C.sub.1-3 -alkoxy-carbonylmethylaminocarbonyl group, and
- R.sub.3 is an isoquinolin-8-yl group,
- or a tautomer or pharmaceutically acceptable salt thereof.
- 6. The disubstituted bicyclic heterocycle of the formula Ia according to claim 5, wherein R.sub.a is an R.sub.3 --SO.sub.2 --R.sub.4 N-- group, or a tautomer or pharmaceutically acceptable salt thereof.
- 7. A compound of the formula I in accordance with claim 1, selected from the group consisting of:
- (a) 1-methyl-2-[(4-amidinophenyl)-oxymethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole;
- (b) 1-methyl-2-[2-(4-amidinophenyl)-ethyl]-5-[N-(N'-(hydroxycarbonylmethyl)-aminocarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole;
- (c) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole; and
- (d) 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-indole,
- or a tautomer or pharmaceutically acceptable salt thereof.
- 8. A pharmaceutical composition containing a compound according to claim 1, 2, 3, 4, 5, 6, 7, or 10, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.
- 9. A method for the treatment of venous and arterial thrombotic diseases which comprises administering to a host in need of such treatment an antithrombotic amount of a compound in accordance with claim 1, 2, 3, 4, 5, 6, 7, or 10, wherein E is an R.sub.b NH--C(.dbd.NH)-- group.
- 10. A compound of the formula I in accordance with claim 1, comprising 1-methyl-2-[N-(4-amidinophenyl)-aminomethyl]-5-[N-(hydroxycarbonylmethyl)-quinoline-8-sulphonylamino]-benzimidazole.
Priority Claims (1)
Number |
Date |
Country |
Kind |
198 34 751 |
Aug 1998 |
DEX |
|
RELATED APPLICATIONS
Benefit of U.S. Provisional Application Ser. No. 60/098,838, filed on Sep. 2, 1998 is hereby claimed.
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 540 051 |
May 1993 |
EPX |
WO97 30971 |
Aug 1997 |
WOX |
WO97 21437 |
Jun 1999 |
WOX |